When combined with quizartinib, p300/CBP inhibitors exhibited synergistic effects in both FLT3-ITD AML xenograft models and AML patient samples by simultaneously suppressing H3K27 acetylation, c-Myc and FLT3 pathways. Here, CREBBP is linked to acute myeloid leukemia.